PROTOCOL AMENDMENT
GYNECOLOGIC

Participation on this trial is limited to select NRG Oncology Phase I approved sites.

NRG-GY017: "Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer.

NCI Version Date: November 8, 2018

Memo posted on NRG Oncology.
Protocol documents will be available to Phase I participating sites on the CTSU website shortly.

 

 

Phase I Participating Sites
  

PA075

Abramson Cancer Center at the University of Pennsylvania

AZ151

Arizona Cancer Center

OH027

Cleveland Clinic Foundation

PA086

Fox Chase Cancer Center

MD017

Johns Hopkins University/Sidney Kimmel Cancer Center

GA020

Georgia Regents University

CT009

Hartford Hospital

TX035

M.D. Anderson Cancer Center

NY016

Memorial Sloan Kettering Cancer Center

WI013

Froedtert and the Medical College of Wisconsin

OH007

Ohio State University

OK003

Oklahoma University

NY158

Roswell Park Cancer Institute

PA121

Thomas Jefferson University

CA189

UC Davis Medical Center

CA088

CA249

University of California Medical Center at Irvine-Orange Campus

University of California San Diego Medical Center

OH274

UHHS – Chagrin Highlands Medical Center

IL057

University of Chicago

CO070

University of Colorado Cancer Center

OH029

Case Western Reserve University

IA018

University of Iowa Hospitals and Clinics

PA015

University of Pittsburgh Cancer Center

VA009

University of Virginia Health Systems

VA010

Virginia Commonwealth University

MO011

Washington University School of Medicine

RI012

Women’s and Infants Hospital

TX011

University of Texas – Southwestern

AL002

University of Alabama

 

Twitter

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address